Based on results of CAPItello-281 which prospectively defined PTEN-deficient disease and showed TRUQAP combination reduced risk of radiographic disease progression or death by 19% ...
Switching to camizestrant led to a 99% median reduction in total ctDNA vs. a 64% increase for patients who remained on standard of care 51% of patients...
Positive overall survival trend in favor of STRIDE regimen with lenvatinib and TACE
Based on POTOMAC Phase III trial results which showed a 32% reduction in the risk of high-risk disease recurrence, progression or death after one year of IMFINZI added to BCG vs. BCG alone
AstraZeneca and Daiichi Sankyo’s DATROWAY is the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting vs. chemotherapy, with an unprecedented median overall survival...
EMERALD-3 late-breaking presentation will showcase benefit of IMFINZI ® (durvalumab) and IMJUDO ® (tremelimumab-actl) in early liver...
With U.S. federal debt exceeding 100% of GDP, VXUS and IXUS offer investors international equity exposure as a hedge against rising sovereign risk.
Approval based on BaxHTN Phase III results showing statistically significant and clinically meaningful reduction in systolic blood pressure in patients with uncontrolled or resistant hypertension ...
Approved for use before surgery based on DESTINY-Breast11 Phase III trial Approved for use following surgery based on DESTINY-Breast05 Phase III trial...
/The%20Cerebras%20logo%20displayed%20on%20a%20smartphone%20screen%20by%20Rafael%20Henrique%20via%20Shutterstock.jpeg)
The Cerebras IPO is the most significant debut in the semiconductor industry since Arm.